Reducing the costs of diabetes in Europe: Preventing complications is the key

September 28, 1999

Brussels, Belgium, Tuesday 28 September 1999: The first pan-European study to evaluate the overall cost of individuals with type 2 diabetes reveals that urgent action is needed to reduce the devastating long-term complications of the disease, if costs are to be kept under control.

"We are facing a potential crisis," warned Professor Massimo Massi-Benedetti, President of the International Diabetes Federation, European region, "the key to improving the quality of life of people with type 2 diabetes and to reducing future costs is to address the long-term complications of the disease."

Initial results from the CODE-2* (Costs of Diabetes in Europe--Type 2) study were presented today at a press briefing at the annual meeting of the European Association for the Study of Diabetes (EASD) in Brussels:Type 2 diabetes represents approximately 90% of diabetes cases1 but, unlike type 1, or so-called "juvenile" diabetes, it develops later in life and starts with mild symptoms, which can sometimes go undetected. It is only in the later stages of the disease that individuals may need regular insulin injections. Satisfactory blood glucose control can sometimes be achieved using diet and exercise or traditional oral anti-diabetic medicines, such as sulfonylureas.

However, damage to the circulatory system still occurs, and many individuals with type 2 diabetes face progressive small blood vessel (microvascular) complications, including eye disease, kidney problems leading to dialysis, and nerve damage which can sometimes result in amputation. Large blood vessel (macrovascular) complications are even more common, and individuals with type 2 diabetes have more than double the risk of dying from conditions associated with cardiovascular disease, such as angina, heart attack and stroke. The CODE-2* results demonstrate the profound effect that these macrovascular complications have on healthcare costs.

New oral treatments, the thiazolidinediones (also known as glitazones), may hold the key to reducing these costs. The thiazolidinediones reduce insulin resistance--the failure of cells in the body to respond correctly to insulin. Insulin resistance is believed to be one of the fundamental defects in type 2 diabetes.
-end-
Notes to Editors

The CODE-2* study began in 1998. Since then, data has been collected for more than 7,000 patients in eight European countries, using patient and practitioner surveys. All survey data was captured on a sophisticated internet technology platform in an effort to ensure a high level of data quality and consistency. The study measures all direct medical costs of type 2 diabetes patients, as well as quality of life and lost productivity due to illness and early retirement.

The CODE-2* study investigated the costs associated with type 2 diabetes patients in eight European countries: Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the UK.

CODE-2* is supported by an educational grant from SmithKline Beecham plc.

For further information about type 2 diabetes, insulin resistance, current therapies, the CODE-2* study methodology and more details about the results, please see the following fact sheets: References

  1. American Diabetes Association. Economic Consequences of Diabetes Mellitus in the U.S. in 1997. Diabetes Care 1998; 21:296-309.
  2. Kobayashi M. Effects of Current Therapeutic Interventions on Insulin Resistance. Diabetes, Obesity and Metabolism 1999; 1: (Supplement 1):S32-S40.
  3. Balkau B & Eschwège E. Insulin resistance: An Independent Risk Factor for Cardiovascular Disease. Diabetes, Obesity and Metabolism 1999; 1: (Supplement 1):S23-S31.
  4. 4. Reasner CA. Promising New Approaches. Diabetes, Obesity and Metabolism 1999; 1: (Supplement 1):S41-S48.
  5. Groop LC. Insulin resistance: The Fundamental Trigger of Type 2 Diabetes. Diabetes, Obesity and Metabolism 1999; 1: (Supplement 1):S1-S7.
  6. Saltiel AR & Olefsky JM. Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes. Diabetes 1996; 45:1661-1669.


The data from the CODE-2* study are for general information only.

MediTech Media Ltd.

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.